Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIBEA vs CEI for Breakthrough Pain in Laboring Nulliparous Women
NCT06494280Recruiting
- Sponsor
- Holy Family Hospital
- Start
- Sep 2024
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial of bupivacaine hydrochloride 0.75% injection and fentanyl in breakthrough pain (2 arms), sponsored by Holy Family Hospital. Primary endpoint: Incidence of breakthrough pain at 48 hours. Started Sep 2024; status: recruiting.
02
Drugs
bupivacaine hydrochloride 0.75% injectionfentanyl
03
Conditions
breakthrough pain
Beyond the preview
Go deeper on NCT06494280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494280.